NCT04218409View on ClinicalTrials.gov

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 2, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pain
Interventions
DRUG

OxyCODONE 5 mg Oral Tablet

Oral oxycodone 5 mg orally

DRUG

Oxytocin nasal spray

Intranasal oxytocin administration (48 IU)

OTHER

Placebo Oxycodone

Oxycodone 0 mg orally

OTHER

Placebo oxytocin

Intranasal placebo administration

DRUG

OxyCODONE 2.5 mg Oral Tablet

Oral oxycodone 2.5 mg orally

Trial Locations (1)

32611

RECRUITING

University of Florida, Gainesville

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Florida

OTHER